CA3005103A1 - Process for making benzoxazepin compounds - Google Patents

Process for making benzoxazepin compounds

Info

Publication number
CA3005103A1
CA3005103A1 CA3005103A CA3005103A CA3005103A1 CA 3005103 A1 CA3005103 A1 CA 3005103A1 CA 3005103 A CA3005103 A CA 3005103A CA 3005103 A CA3005103 A CA 3005103A CA 3005103 A1 CA3005103 A1 CA 3005103A1
Authority
CA
Canada
Prior art keywords
bromo
acid
ethyl
solution
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3005103A
Other languages
English (en)
French (fr)
Inventor
Remy Angelaud
Danial BEAUDRY
Diane CARRERA
Sushant Malhotra
Travis Remarchuk
Fredric ST-JEAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3005103A1 publication Critical patent/CA3005103A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3005103A 2013-03-13 2014-03-12 Process for making benzoxazepin compounds Abandoned CA3005103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
CA2948765A CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2948765A Division CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds

Publications (1)

Publication Number Publication Date
CA3005103A1 true CA3005103A1 (en) 2014-09-18

Family

ID=50241450

Family Applications (6)

Application Number Title Priority Date Filing Date
CA3005103A Abandoned CA3005103A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA2897618A Abandoned CA2897618A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
CA2948763A Expired - Fee Related CA2948763C (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005118A Abandoned CA3005118A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA2948765A Abandoned CA2948765A1 (en) 2013-03-13 2014-03-12 Intermediate (4-bromo-2-fluorophenyl)-1h-imidazoyl derivatives for use in a process to synthesize benzoxazepin compounds
CA2897618A Abandoned CA2897618A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
CA3005112A Abandoned CA3005112A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP3404032B1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR101871133B1 (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA3005103A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2649976C2 (enExample)
SG (2) SG11201507394RA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3083640A1 (en) 2013-12-16 2016-10-26 F. Hoffmann-La Roche AG Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
TWI649326B (zh) 2015-07-02 2019-02-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其製備方法
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
JP7036724B2 (ja) * 2016-07-29 2022-03-15 日本たばこ産業株式会社 ピラゾール－アミド化合物の製造方法
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
ES2953833T3 (es) 2016-12-15 2023-11-16 Hoffmann La Roche La invención se refiere a procedimientos de preparación de compuestos de benzoxacepina oxazolidinona e intermedios útiles
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
EP1123281B1 (en) * 1998-10-23 2003-10-22 Dow AgroSciences LLC 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
US8828902B2 (en) 2001-07-12 2014-09-09 Reaxa Limited Microencapsulated catalyst methods of preparation and method of use thereof
US20050014805A1 (en) * 2001-10-12 2005-01-20 Chenzhi Zhang Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
CA2667428A1 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
JP2010516680A (ja) * 2007-01-19 2010-05-20 エックスカバリー，インコーポレイテッド キナーゼ阻害薬化合物
EP2214675B1 (en) * 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
RU2525389C2 (ru) * 2008-02-21 2014-08-10 Мерк Шарп И Доум Корп. Соединения, которые являются ингибиторами erk
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
CA2772691C (en) * 2009-09-28 2017-10-03 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
CA2778684A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
BR112013024122A2 (pt) * 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물

Also Published As

Publication number Publication date
AU2016204432B2 (en) 2017-12-07
SG10201706760YA (en) 2017-10-30
WO2014140073A1 (en) 2014-09-18
JP2019089762A (ja) 2019-06-13
EP3404032A3 (en) 2019-03-13
MX2015011438A (es) 2016-02-03
AU2014230812A1 (en) 2015-09-03
EP3404032A2 (en) 2018-11-21
RU2018109979A (ru) 2019-02-28
CN105377856B (zh) 2018-05-22
JP2020114814A (ja) 2020-07-30
IL240793A0 (en) 2015-10-29
EP3845540A1 (en) 2021-07-07
JP6363120B2 (ja) 2018-07-25
JP2018008959A (ja) 2018-01-18
JP2018150298A (ja) 2018-09-27
BR112015020716A2 (pt) 2017-07-18
AU2014230812A8 (en) 2015-09-10
JP2016512209A (ja) 2016-04-25
RU2649976C2 (ru) 2018-04-06
CA2948765A1 (en) 2014-09-18
KR101821468B1 (ko) 2018-01-23
EP2970329A1 (en) 2016-01-20
US9303043B2 (en) 2016-04-05
CA3005118A1 (en) 2014-09-18
CA2897618A1 (en) 2014-09-18
CN105377856A (zh) 2016-03-02
AU2014230812B2 (en) 2016-04-07
AU2018201393A1 (en) 2018-03-15
NZ711192A (en) 2019-04-26
AU2016204432A1 (en) 2016-07-21
EP3404032C0 (en) 2025-07-02
CN108929333A (zh) 2018-12-04
AR095365A1 (es) 2015-10-14
SG11201507394RA (en) 2015-10-29
KR20150119033A (ko) 2015-10-23
JP6442005B2 (ja) 2018-12-19
US20140275523A1 (en) 2014-09-18
KR20180070715A (ko) 2018-06-26
KR101871133B1 (ko) 2018-06-25
CA3005112A1 (en) 2014-09-18
JP6663459B2 (ja) 2020-03-11
JP2019031493A (ja) 2019-02-28
HK1215433A1 (zh) 2016-08-26
EP3404032B1 (en) 2025-07-02
KR20170070270A (ko) 2017-06-21
CA2948763A1 (en) 2014-09-18
CA2948763C (en) 2018-04-24
RU2015138488A (ru) 2017-04-20

Similar Documents

Publication Publication Date Title
EP3404032B1 (en) Process for making benzoxazepin compounds
KR20220042204A (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
CA2962321A1 (en) Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
CA3156594A1 (en) Heterocyclic rip1 inhibitory compounds
WO2020079652A1 (en) Kinase inhibitors
CA2977752A1 (en) Benzimidazole compound for preventing or treating a disease caused by abnormal prs activity, method for preparing the same and pharmaceutical composition comprising the same
CN111018839B (zh) 三氮唑醇类衍生物及其制备方法和应用
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
EA021781B1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
WO2025256640A1 (zh) 大环化合物及其药物组合物和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180516

FZDE Discontinued

Effective date: 20200312